📊 Score Breakdown
🌦️ Dilution Forecast
💹 Market Data
🏛 Institutional Holdings
📉 Short Interest
📁 Recent SEC Activity
📰 Recent News
📋 What This Means for CERO Shareholders
CERo Therapeutics Holdings, Inc. (CERO) has a DilutionScore of 48/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.
CERO has an active ATM (at-the-market) program with $729.6M remaining capacity. ATM programs allow companies to sell shares continuously into the open market through a broker-dealer — without announcing a secondary offering. This creates a silent but steady source of share dilution that shows up in quarterly share count increases rather than a discrete offering event. DilutionWatch tracks 159,724 outstanding warrants for CERO. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window.
DilutionWatch tracks over 25 SEC filing types for CERO in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for CERO alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.
🔗 Related Stocks — MEDIUM Risk
Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.